SOLRIAMFETOL TAB
Clinical Criteria Summary
Exclusion Criteria
- OSA not receiving primary OSA therapy (e.g., CPAP, or other OSA therapy for patients for whom CPAP was intolerable or ineffective (dental appliance, hypoglossal nerve stimulator, OSA surgery, or other)
- Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of a MAOI within the preceding 14 days
- Patient has uncontrolled hypertension, unstable non medically controlled angina or coronary artery disease, non medically controlled heart arrhythmias, or other clinically relevant unstable or untreated heart problems
- End Stage Renal Disease (eGFR less than 15 ml/min/1.73m2)
Inclusion Criteria & Indications
- Treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA)
- Documented lack of efficacy with, is intolerant of, or has contraindications to modafinil OR armodafinil
Diagnostic Requirements
- If narcolepsy is the indication, the diagnosis of narcolepsy has been confirmed by Multiple Sleep Latency Test (MSLT) or hypocretin-1 deficiency
- Documented excessive daytime sleepiness (Epworth Sleepiness Scale score > 10)
Monitoring & Prescribing Requirements
- Prescribed and monitored by a VA/VA Community Care sleep specialist/pulmonologist/neurologist or locally designated expert in sleep disorders.